Previous 10 | Next 10 |
Shares of Synlogic (SYBX +11.6%) are trading higher today after Oppenheimer initiated the stock with a buy rating and $7 price target (~192% upside). Analyst Mark Breidenbach says that given interim phase 2 data presented this week on SYNB1618 for phenylketonuria, "we are increasingly convinc...
Check Out These 4 Trending Biotech Stocks Right Now Biotech stocks have been among the most exciting stocks to invest in the stock market . The reason being, this is a high-risk, high-reward industry that could appeal to a certain group of investors. The stock movement within th...
William Blair analyst Tim Lugo upgraded BioMarin Pharmaceutical (NASDAQ:BMRN) to Outperform from Market Perform without a price target after the FDA granted conditional approval to Voxzogo. Recently on November 19, the FDA granted approval to BioMarin's Voxzogo (vosoritide) for short stature ...
The FDA has granted approval to BioMarin Pharmaceutical's (BMRN +5.6%) Voxzogo (vosoritide) for short stature due to achondroplasia. The treatment, the first for achondroplasia, targets the underlying cause of the condition. The approval was based on improvement in annual growth velocity...
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates 1st Therapeutic Treatment for Achondroplasia, Most Common Form of Disproportionate Short Statu...
Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform Canada NewsWire -- Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases ...
New York, New York--(Newsfile Corp. - November 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and reminds investors of the December 22, 2021 deadli...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 11, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law...
BioMarin has 6 commercialised assets in the rare disease space, targeting e.g. lysosomal storage diseases. The company is on track for ~$1.8bn of revenues in FY21, and importantly, a small non-GAAP net income, reversing years of heavy losses. The company also has a PDUFA date on N...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...